Benazepril Hydrochloride

Fact.MR, a global research & consulting firm, in their latest edition of the report, projected that the renovascular hypertension treatment market is anticipated to see moderate growth pace in 2021 and beyond. Increase in initiatives undertaken by private and public healthcare organisations for the management of kidney diseases, which will spearhead the expansion of the renovascular hypertension treatment industry. “Renovascular hypertension treatment industry will be growing moderately due to increase in the occurrence of primary renal ailments, such as focal segmental glomerulosclerosis, atherosclerosis and renal artery stenosis.” states Fact.MR. Changing Lifestyle of People Influencing Industry Growth Unhealthy lifestyle, obesity, stress, rise in smoking and the higher prevalence of cholesterols & diabetes are amid aspects projected to drive the renovascular hypertension treatment industry. Furthermore, increased consumption of ready-to-eat food products, as well as absence of physical activity of individuals, upsurge the chances for high blood pressure and hypertension. Several researches and studies have revealed a clear link between rise in blood pressure and the consumption of high levels of salt. Request a report sample to gain comprehensive market insights at - Why is Demand from ACE inhibitors More? Angiotensin-Converting Enzyme (ACE) inhibitor will be contributing majority of the revenue share in the approaching years. ACE inhibitors given for the treatment of renovascular hypertension intrude the adaptation of angiotensin I and angiotensin II. Enalapril, captopril, ramipril, lisinopril, and benazepril are the general ACE inhibitors utilized for treatment of renovascular hypertension. In addition to ACE inhibitors, diuretic drugs and angiotensin II receptor blockers are also prescribed by healthcare professionals for the kidney to remove fluid from the blood. What are the Factors Responsible for Industry Growth in the US? The US has been found to hold a major share for the renovascular hypertension treatment owing to exceedingly supportive government initiatives. Also majority of market players have been attaining approval for the clinical trials from the FDA, in the region. Germany and the UK are anticipated to have the second-biggest share due to the increasing awareness pertaining to major health issues registered for drug-resistant hypertension. Emerging regions such as China, India and South Korea is likely to catch up with the progressions in healthcare infrastructure, as well as rise in healthcare expenditure and facilities. Moreover, the existence of a huge target population base in economies such as China and Japan are the main drivers for renovascular hypertension treatment. Get Customization on this Report for Specific Country New Drug Development Remain Key Focus Area: Fact.MR Survey The renovascular hypertension treatment market appears consolidated. Fact.MR’s survey reflected that the major companies are engaged in conducting clinical trials for development of novel treatment drugs for renovascular hypertension. The updated edition of the report offer all-inclusive coverage of the anticipated to remain significant strategies of the companies. A few of the key companies profiled in the report are Pfizer Inc., Abbott Laboratories, Novartis AG, AstraZeneca plc., Merck & Company, Inc., Johnson and Johnson, Sanofi SA, Eli Lilly and Company, Bayer AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, and others. The latest edition also provides a comprehensive analysis of the COVID-19 impact on this market. Explore Fact.MR’s Healthcare Reports Atherosclerotic Renovascular Treatment Market: Delve into Fact.MR’s extensive study on the atherosclerotic renovascular treatment market, offering detailed assessment. The study analyses crucial trends that are currently determining, and those which are expected to shape future expansion trajectory, shedding light on the vital dynamics such as drivers, restraints and opportunities. Renal Artery Stenosis Treatment Market: The global renal artery stenosis treatment market study published by fact.mr incorporates detailed assessment of the market landscape, taking into consideration value chain analysis, business execution and supply chain analysis across key markets. Renal Drugs Market: Fact.MR’s global renal drugs market research report provides stakeholders with an exhaustive analysis on key market dynamics, such as the drivers, restraints, opportunities and trends responsible for shaping the future expansion trajectory. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Sudip Saha US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Corporate Headquarter: Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates Source: Fact.MR

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the United States District Court for the District of New Jersey has vacated a temporary order restraining Teva's launch of its amlodipine besylate/benazepril products, AB rated to Novartis' Lotrel®. Instead, the Court has ordered Teva and Novartis not to sell or offer further generic product, beyond what has already been commercialized, including any authorized generics, until at least the completion of a status call with the Judge next Tuesday, May 29, 2007.